United States, Jan. 2 -- United States based ADAPTIVE BIOTECHNOLOGIES CORPORATION has secured contract from Veterans Affairs, Department Of for Q301 - Clonoseq Measurable Residual Disease (Mrd) Testing Services. The value of the contract is worth 243750 USD.
Published by HT Digital Content Services with permission from Pivotal Sources....